Merck Sharp & Dohme (Australia) Pty Limited is pleased to be partnering with PharmaPrograms to provide community pharmacies with the opportunity to participate in the Lagevrio® Pharmacy Program. Lagevrio® has provisional approval for the treatment of adults with COVID-19 who do not require initiation of oxygen due to COVID-19 and who are at increased risk for hospitalisation or death. This pharmacist-led program aims to improve medication compliance and adherence by facilitating communication between pharmacists and patients.